Objective Evaluation of the off-label use of flupentixol melitracen based on an evidence-based medicine approach and recommendations for graded management.Methods The off-label prescriptions of flupentixol melitracen for outpatient clinics in our hospital from November 1,2023,to October 31,2024,were collected to count the clinical diagnoses of off-label use of flupentixol melitracen tablets.Searching foreign drug manuals,authoritative medical monographs,as well as guidelines and literature databases such as the US National Guidelines Clearinghouse(NGC),Guidelines International Network(GIN),Medlive,Yaozh.com,PubMed,Cochrane Library,Embase,WanFang Data,VIP,CNKI and other guidelines and literature databases,to collect literature on evidence-based medical evidence related to the flupentixol melitracen tablets for off-label use.The literature was screened according to the pre-established inclusion and exclusion criteria,and the quality of evidence was assessed and graded to determine the evidence of evidence-based medicine for off-label use,and to make recommendations for grading management.Results Flupentixol melitracen tablets off-label use involves 13 clinical diagnoses of gastritis,sleep disorders,dizziness,neurological disorders,gastroesophageal reflux,gastrointestinal disorders,headache(tension-type headache),abdominal pain(functional abdominal pain syndrome),palpitations,constipation,neurasthenia,cardiac neurosis,and neuralgia.A total of 8 evidence-based medical literature related to off-label use were included,including 4 guidelines,1 Meta-analysis,and 3 clinical randomised controlled trials(RCTs).Based on the evaluation of evidence-based medicine methodology,the quality grade of a Meta-analysis was extremely low,and 3 RCTs were at high risk of bias.There was evidence-based medical evidence for the determination of treating chronic gastritis,which is recommende as level A management and agreed to be used.There was evidence-based medical evidence for the adjudication of treating sleep disorders,headache(tension-type headache),abdominal pain(functional abdominal pain syndrome),neuralgia,and chronic constipation,which was recommended as level B management and restriction for use.There was no evidence-based medical evidence for the remaining off-label uses of the drug.Conclusion The evidence-based medicine evidence for flupentixol melitracen in the treatment of chronic gastritis,sleep disorders,headache,abdominal pain,neuralgia,and chronic constipation are relatively sufficient and their use are reasonable,while the rationale for other off-label use are relatively low and are recommended to be contraindicated.Through the evidence-based medicine methods,the evaluation system for off-label use of flupentixol melitracen has been improved,providing a basis for rational clinical medication and ensuring the safety of patients' medication.

Objective Evaluation of the off-label use of flupentixol melitracen based on an evidence-based medicine approach and recommendations for graded management.Methods The off-label prescriptions of flupentixol melitracen for outpatient clinics in our hospital from November 1,2023,to October 31,2024,were collected to count the clinical diagnoses of off-label use of flupentixol melitracen tablets.Searching foreign drug manuals,authoritative medical monographs,as well as guidelines and literature databases such as the US National Guidelines Clearinghouse(NGC),Guidelines International Network(GIN),Medlive,Yaozh.com,PubMed,Cochrane Library,Embase,WanFang Data,VIP,CNKI and other guidelines and literature databases,to collect literature on evidence-based medical evidence related to the flupentixol melitracen tablets for off-label use.The literature was screened according to the pre-established inclusion and exclusion criteria,and the quality of evidence was assessed and graded to determine the evidence of evidence-based medicine for off-label use,and to make recommendations for grading management.Results Flupentixol melitracen tablets off-label use involves 13 clinical diagnoses of gastritis,sleep disorders,dizziness,neurological disorders,gastroesophageal reflux,gastrointestinal disorders,headache(tension-type headache),abdominal pain(functional abdominal pain syndrome),palpitations,constipation,neurasthenia,cardiac neurosis,and neuralgia.A total of 8 evidence-based medical literature related to off-label use were included,including 4 guidelines,1 Meta-analysis,and 3 clinical randomised controlled trials(RCTs).Based on the evaluation of evidence-based medicine methodology,the quality grade of a Meta-analysis was extremely low,and 3 RCTs were at high risk of bias.There was evidence-based medical evidence for the determination of treating chronic gastritis,which is recommende as level A management and agreed to be used.There was evidence-based medical evidence for the adjudication of treating sleep disorders,headache(tension-type headache),abdominal pain(functional abdominal pain syndrome),neuralgia,and chronic constipation,which was recommended as level B management and restriction for use.There was no evidence-based medical evidence for the remaining off-label uses of the drug.Conclusion The evidence-based medicine evidence for flupentixol melitracen in the treatment of chronic gastritis,sleep disorders,headache,abdominal pain,neuralgia,and chronic constipation are relatively sufficient and their use are reasonable,while the rationale for other off-label use are relatively low and are recommended to be contraindicated.Through the evidence-based medicine methods,the evaluation system for off-label use of flupentixol melitracen has been improved,providing a basis for rational clinical medication and ensuring the safety of patients' medication.

Objective To investigate the effects of citric acid on the related indexes of salivary secretion under acid loading in or‐der to optimize the citric acid load method .Methods The saliva samples were collected from 10 young healthy volunteers at 1-90 s before ,at 91-120 s during and at 121-210 s after citric acid loading .The indexes were detected in saliva with mixed loading and after loading .The salivary alpha‐amylase(sAA ) activity ,pH value ,saliva flow rate ,total protein concentration in various groups were detected .The ratio values before and after the acid loading were compared among the groups .Results (1)The sAA activity , saliva pH value and total protein concentrations after acid loading were significantly increased compared before loading (P<0 .05) , moreover the ratio of after loading and before loading was greater than 1(P<0 .05);(2) however in the citric acid mixing ,the sAA activity ,saliva pH value and total protein concentration were decreased compared with before acid loading ,its ratio was less than 1 (P<0 .05) .Conclusion Citric acid affects the secretion result of acid loading saliva secretion ,it is suggested that the saliva under acid loading is separated treated and analyzed .

Objective:In order to achieve the use of community medical care and branch doctor resources, to provide monitoring of remote diagnosis, providing more convenient, safe and efficient medical service for patients and hospital objective. Methods:Multi parameter remote monitoring system design of special model of WIFI wireless technology, including special new WIFI module, wearable multi parameter telemetry monitor, wireless relay box network and medical monitoring software, testing and data transmission of ECG, respiration, blood oxygen using a wireless network, can the patient monitoring in normal life condition. Results:Whenever and wherever possible the electrophysiological data sent to the hospital, the doctor can according to the electrophysiological data of the patient for remote diagnosis and further treatment. The accuracy of the stability, the reliability of the system and the parameters of the tested strictly, data transmission accurate rate reaches more than 98%. Conclusion: The patients and doctors have been received good feedback, clinical trials, has very practical clinical significance.